STOCK TITAN

Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) will announce its Q4 and full-year 2023 financial results on February 22, 2024. The senior management team will hold a conference call to discuss the results and company updates.
Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its fourth quarter and full year 2023 financial results on Thursday, February 22, 2024. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.

To access the conference call, please dial +1 (800) 836-8184 (U.S. & Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call. A live audio webcast of the call will be available under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events. The webcast will be archived and available for replay for 90 days following the event.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is committed to supporting and creating more moments for the neurodegenerative community through the discovery and development of innovative new treatments. Amylyx is headquartered in Cambridge, Massachusetts and has operations in Canada, EMEA, and Japan. For more information, visit amylyx.com and follow us on LinkedIn and X, formerly known as Twitter. For investors, please visit investors.amylyx.com.

Media

Amylyx Media Team

+1 (857) 799-7274

amylyxmediateam@amylyx.com



Investors

Lindsey Allen

Amylyx Pharmaceuticals, Inc.

+1 (857) 320-6244

Investors@amylyx.com

Source: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) will announce its Q4 and full-year 2023 financial results on Thursday, February 22, 2024.

The conference call to discuss the financial results and company updates will be held at 8:00 a.m. ET.

To access the conference call, please dial +1 (800) 836-8184 (U.S. & Canada) or +1 (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Amylyx Pharmaceuticals call.

The live audio webcast of the call will be available under 'Events and Presentations' in the Investor section of the Company’s website, https://investors.amylyx.com/news-events/events.
Amylyx Pharmaceuticals Inc

NASDAQ:AMLX

AMLX Rankings

AMLX Latest News

AMLX Stock Data

Medicinal and Botanical Manufacturing
Manufacturing
Link

About AMLX

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis.